J. Safra Sarasin Holding AG Invests $699,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

J. Safra Sarasin Holding AG purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 36,453 shares of the company's stock, valued at approximately $699,000.

A number of other hedge funds also recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its stake in shares of Viridian Therapeutics by 824.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 34,172 shares of the company's stock valued at $655,000 after purchasing an additional 30,475 shares in the last quarter. MetLife Investment Management LLC increased its stake in Viridian Therapeutics by 21.8% in the fourth quarter. MetLife Investment Management LLC now owns 44,295 shares of the company's stock valued at $849,000 after purchasing an additional 7,914 shares in the last quarter. Farringdon Capital Ltd. acquired a new stake in Viridian Therapeutics during the 4th quarter worth $329,000. XTX Topco Ltd bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at about $440,000. Finally, Barclays PLC boosted its holdings in shares of Viridian Therapeutics by 25.9% in the fourth quarter. Barclays PLC now owns 157,860 shares of the company's stock valued at $3,027,000 after buying an additional 32,463 shares during the period.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Needham & Company LLC reissued a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Trading Down 2.4 %

Shares of VRDN stock traded down $0.33 during mid-day trading on Tuesday, reaching $13.21. 102,677 shares of the stock traded hands, compared to its average volume of 1,196,718. The stock's fifty day simple moving average is $14.18 and its two-hundred day simple moving average is $18.14. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -3.07 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.